Vimarsana
Biggest News Aggregation in the World

Page 14 - Eqs Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eqs Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eqs Group Today - Breaking & Trending Today

DGAP-Adhoc: Beaconsmind AG releases its full-year results for the period July 2020 to June 2021, with 56% growth in revenue - Vimarsana News

DGAP-Adhoc: Beaconsmind AG releases its full-year results for the period July 2020 to June 2021, with 56% growth in revenue

EQS Group-Ad-hoc: Beaconsmind AG / Key word(s): Annual Results Beaconsmind AG releases its full-year results for the period July 2020 to June 2021, with 56% growth in revenue 29-Oct-2021 / 20:30 CET/CEST Disclosure

EQS-Adhoc: Dufry International AG: Dufry reports acceleration on turnover and strong positive cash flow in Q3 2021 - Vimarsana News

EQS-Adhoc: Dufry International AG: Dufry reports acceleration on turnover and strong positive cash flow in Q3 2021

EQS Group-Ad-hoc: Dufry International AG / Key word(s): Quarter Results Dufry reports acceleration on turnover and strong positive cash flow in Q3 2021 28-Oct-2021 / 07:00 CET/CEST Release of an

EQS-News: Nordea Bank Abp: Transaction in Own Shares - Vimarsana News

EQS-News: Nordea Bank Abp: Transaction in Own Shares

EQS Group-News: Nordea Bank Abp / Key word(s): Transaction in Own Shares Nordea Bank Abp: Transaction in Own Shares 28.10.2021 / 09:15 Nordea Bank Abp: Repurchase of own shares on

EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients - Vimarsana News

EQS-Adhoc: RELIEF THERAPEUTICS Holding AG: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients

EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Study results Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical

EQS-Adhoc: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients - Vimarsana News

EQS-Adhoc: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients

EQS Group-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Study results Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients 27-Oct-2021 / 07:00 CET/CES...